<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">106689</article-id><article-id pub-id-type="doi">10.7554/eLife.106689</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Pulmonary Hypertension</subject></subj-group></article-categories><title-group><article-title>When cell teamwork turns toxic</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khoury</surname><given-names>Wadih EI</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5635-9643</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Wadih EI Khoury</bold> is in the Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh, School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, United States</p></bio></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chan</surname><given-names>Stephen Y</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9520-7527</contrib-id><email>chansy@pitt.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/><bio><p><bold>Stephen Y Chan</bold> is in the Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh, School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, United States</p></bio></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04ehecz88</institution-id><institution>Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh, School of Medicine and University of Pittsburgh Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>04</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e106689</elocation-id><permissions><copyright-statement>© 2025, Khoury and Chan</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Khoury and Chan</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-106689-v1.pdf"/><related-article related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.7554/eLife.98558" id="ra1"/><abstract><p>In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>pulmonary artery</kwd><kwd>adventitial fibroblasts</kwd><kwd>vascular smooth muscle cells</kwd><kwd>pulmonary hypertension</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Template</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Crnkovic S, Puthenparampil HT, Mulch S, Biasin V, Radic N, Wilhelm J, Bartkuhn M, Rad EB, Wawrzen A, Matzer I, Mitra A, Leib R, Nagy BM, Sahu-Osen A, Valzano F, Bordag N, Evermann M, Hoetzenecker K, Olschewski A, Ljubojevic-Holzer S, Wygrecka M, Stenmark K, Marsh LM, de Jesus Perez V, Kwapiszewska G. 2025. Adventitial fibroblasts direct smooth muscle cell-state transition in pulmonary vascular disease. <italic>eLife</italic> <bold>13</bold>:RP98558. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.98558">10.7554/eLife.98558</ext-link>.</p></boxed-text><p>Cells rely on cues from their environment to develop and work properly. Yet this interdependence can turn perilous when one cell goes rogue, triggering an unchecked cascade of dysfunction. For decades, understanding these toxic cellular relationships has been hindered by a fundamental challenge: the inability to simultaneously study molecular details and tissue-wide interactions. Earlier studies often prioritized one scale at the expense of the other and, because of this, missed critical connections.</p><p>A striking biological example is the cellular interplay in pulmonary hypertension. This life-threatening disease, defined by an increased pressure in the blood vessels of the lungs, often ultimately leads to heart failure and death (<xref ref-type="bibr" rid="bib6">Humbert et al., 2019</xref>). At its roots, pulmonary hypertension arises from the toxic interaction between multiple cell types compromising each other’s normal function (<xref ref-type="bibr" rid="bib5">Frid et al., 2020</xref>). Under healthy conditions, smooth muscle cells in the arteries of the lungs (known as PASMCs) contract and dilate, regulating flow and pressure in the lung vasculature. Their counterparts, the fibroblast cells that form the vessel’s outer layer (or PAAFs), protect PASMCs and mediate communication between the two cell types (<xref ref-type="bibr" rid="bib10">Stenmark et al., 2018</xref>).</p><p>In pulmonary hypertension, however, this partnership turns lethal. PAAFs start remodeling their external environment and secrete signals that cause PASMCs to lose their ability to contract, depriving them of their main function (<xref ref-type="bibr" rid="bib7">Park et al., 2022</xref>). Instead, the PASMCs start stiffening, causing a cascade of irreversible vascular changes that represent a cornerstone in the development of pulmonary hypertension (<xref ref-type="bibr" rid="bib2">Crnkovic et al., 2022</xref>).</p><p>With PAAFs and PASMCs at the forefront of this disease, many questions remain unanswered. What triggers PAAF activation? How do PASMCs lose their contractility? Is there an underlying shared mechanism linking PAAF and PASMC dysfunction? <xref ref-type="bibr" rid="bib2">Crnkovic et al., 2022</xref> Answering these questions could lead to new and more effective therapies for a number of deadly diseases.</p><p>Now, in eLife, Grazyna Kwapiszewska, Vinicio de Jesus Perez and colleagues at various research institutes in Austria, Germany and the United States – including Slaven Crnkovic and Helene Thekkekara Puthenparampi as joint first authors – report how PAAFs force PASMCs into a diseased state (<xref ref-type="bibr" rid="bib3">Crnkovic et al., 2025</xref>).</p><p>Crnkovic et al. isolated PAAFs and PASMCs from both healthy donors and pulmonary hypertension patients, comparing the gene activity and protein levels between these two groups. They found that diseased PAAFs produced more collagen, which stiffens tissues, while simultaneously underproducing laminin, a protein that provides structure for collagen deposition (<xref ref-type="fig" rid="fig1">Figure 1</xref>). This collagen-laminin imbalance created a rigid environment, similar to a building with too much concrete and not enough scaffolding. The mechanical stress from the stiffened matrix forced PASMCs to abandon their contractile function, a hallmark of their healthy state (<xref ref-type="bibr" rid="bib2">Crnkovic et al., 2022</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Progression from healthy pulmonary artery adventitial fibroblasts (PAAFs) and pulmonary artery smooth muscle cells (PASMCs) to pulmonary hypertension (PH) phenotype.</title><p>In healthy arteries (left), PASMCs are dynamic cells that regulate flow and pressure in the lung vasculature by contracting and dilating, while the fibroblasts on the vessel’s outer layer (PAAFs) protect PASMCs (green triangles). In pulmonary hypertension, PAAFs overproduce collagen and harmful proteins (red triangles) that cause PASMCs to become rigid. Imbalanced protein dynamics and mitochondrial dysfunction in both cell types further contribute to the diseased state (right). Created with <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/wrem3ip">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106689-fig1-v1.tif"/></fig><p>In a parallel mechanism, diseased PAAFs exacerbated dysfunction by overproducing harmful signals while downregulating protective proteins, thus reprogramming PASMCs into a dysregulated state. As dynamic cells require constant energy, PASMCs rely heavily on mitochondria, especially in times of added cellular stress (<xref ref-type="bibr" rid="bib8">Qin et al., 2023</xref>). Given the central role of mitochondria in generating cellular energy, regulating harmful molecules, and maintaining an adequate intracellular balance – all of which are affected in pulmonary hypertension – Crnkovic et al. investigated the mitochondria’s role in reprogramming PAAFs and PASMCs (<xref ref-type="bibr" rid="bib1">Chan et al., 2009</xref>).</p><p>Next, mitochondrial function was evaluated by measuring membrane potential, oxygen consumption and levels of harmful reactive species, which linked the observed mitochondrial compromise to subsequent DNA damage. This analysis revealed that mitochondrial dysregulation occurred when both cell types transitioned to a diseased state. Mitochondria are crucial in protecting the cell’s DNA by neutralizing harmful molecules, especially in diseased states. However, because the mitochondria were damaged, the DNA suffered additional stress, worsening cellular injury.</p><p>In pulmonary hypertension, microenvironment stiffness and mitochondrial dysfunction are two sides of the same coin. The rigid environment forces PASMCs into a state of mechanical stress, overloading their mitochondria. In turn, dysfunctional mitochondria, while unable to protect the DNA, also leak harmful molecules, worsening cellular remodeling. This vicious cycle, where mechanics and metabolism unite, traps the cells in a diseased state leading to irreversible vascular damage. By uncovering these pathways, Crnkovic et al. revealed that targeting PAAF signaling has the potential to reverse PASMC dysfunction in pulmonary hypertension. Halting toxic crosstalk and mitochondrial damage could thus reverse vascular stiffening, a potential therapeutic breakthrough for this disease.</p><p>While this study advances our understanding of pulmonary hypertension, certain limitations must be acknowledged. First, by focusing only on samples from patients with an established disease, early markers of disease triggers remain unexplored (<xref ref-type="bibr" rid="bib9">Stacher et al., 2012</xref>). Second, the study only focused on PASMCs and PAAFs, potentially excluding other significant but understudied cell types in the progression of the condition (<xref ref-type="bibr" rid="bib4">El Kasmi et al., 2014</xref>). Third, the origin of the reported mitochondrial dysfunction, whether a cause or a consequence of pulmonary hypertension, remains unclear.</p><p>By evaluating the interplay between different cell types while pinpointing precise genetic targets, Crnkovic et al. highlight the transformative potential and inherent challenges of studying genes and protein profiles in pulmonary hypertension. Leveraging this approach in future work, researchers may be able to shed light on pulmonary hypertension’s full story and provide a therapeutic road map to restore healthy cell states for a disease with no current cure.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Consultant for Merck, Janssen, and United Therapeutics; director, officer, and shareholder in Synhale Therapeutics; has held grants from Bayer and United Therapeutics; has filed patent applications regarding metabolism and next-generation therapeutics in pulmonary hypertension (US 10,925,869 B2; PCT/US2015/029286; PCT/US2018/062013; US 11,773,391 B2; PCT/IB2023/055431)</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>SY</given-names></name><name><surname>Zhang</surname><given-names>YY</given-names></name><name><surname>Hemann</surname><given-names>C</given-names></name><name><surname>Mahoney</surname><given-names>CE</given-names></name><name><surname>Zweier</surname><given-names>JL</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2</article-title><source>Cell Metabolism</source><volume>10</volume><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2009.08.015</pub-id><pub-id pub-id-type="pmid">19808020</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crnkovic</surname><given-names>S</given-names></name><name><surname>Valzano</surname><given-names>F</given-names></name><name><surname>Fließer</surname><given-names>E</given-names></name><name><surname>Gindlhuber</surname><given-names>J</given-names></name><name><surname>Thekkekara Puthenparampil</surname><given-names>H</given-names></name><name><surname>Basil</surname><given-names>M</given-names></name><name><surname>Morley</surname><given-names>MP</given-names></name><name><surname>Katzen</surname><given-names>J</given-names></name><name><surname>Gschwandtner</surname><given-names>E</given-names></name><name><surname>Klepetko</surname><given-names>W</given-names></name><name><surname>Cantu</surname><given-names>E</given-names></name><name><surname>Wolinski</surname><given-names>H</given-names></name><name><surname>Olschewski</surname><given-names>H</given-names></name><name><surname>Lindenmann</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>YY</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name><name><surname>Marsh</surname><given-names>LM</given-names></name><name><surname>Kwapiszewska</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Single-cell transcriptomics reveals skewed cellular communication and phenotypic shift in pulmonary artery remodeling</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.153471</pub-id><pub-id pub-id-type="pmid">36099047</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crnkovic</surname><given-names>S</given-names></name><name><surname>Puthenparampil</surname><given-names>HT</given-names></name><name><surname>Mulch</surname><given-names>S</given-names></name><name><surname>Biasin</surname><given-names>V</given-names></name><name><surname>Radic</surname><given-names>N</given-names></name><name><surname>Wilhelm</surname><given-names>J</given-names></name><name><surname>Bartkuhn</surname><given-names>M</given-names></name><name><surname>Rad</surname><given-names>EB</given-names></name><name><surname>Wawrzen</surname><given-names>A</given-names></name><name><surname>Matzer</surname><given-names>I</given-names></name><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Leib</surname><given-names>R</given-names></name><name><surname>Nagy</surname><given-names>BM</given-names></name><name><surname>Sahu-Osen</surname><given-names>A</given-names></name><name><surname>Valzano</surname><given-names>F</given-names></name><name><surname>Bordag</surname><given-names>N</given-names></name><name><surname>Evermann</surname><given-names>M</given-names></name><name><surname>Hoetzenecker</surname><given-names>K</given-names></name><name><surname>Olschewski</surname><given-names>A</given-names></name><name><surname>Ljubojevic-Holzer</surname><given-names>S</given-names></name><name><surname>Wygrecka</surname><given-names>M</given-names></name><name><surname>Stenmark</surname><given-names>K</given-names></name><name><surname>Marsh</surname><given-names>LM</given-names></name><name><surname>de Jesus Perez</surname><given-names>V</given-names></name><name><surname>Kwapiszewska</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Adventitial fibroblasts direct smooth muscle cell-state transition in pulmonary vascular disease</article-title><source>eLife</source><volume>13</volume><elocation-id>RP98558</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.98558</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Kasmi</surname><given-names>KC</given-names></name><name><surname>Pugliese</surname><given-names>SC</given-names></name><name><surname>Riddle</surname><given-names>SR</given-names></name><name><surname>Poth</surname><given-names>JM</given-names></name><name><surname>Anderson</surname><given-names>AL</given-names></name><name><surname>Frid</surname><given-names>MG</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Pullamsetti</surname><given-names>SS</given-names></name><name><surname>Savai</surname><given-names>R</given-names></name><name><surname>Nagel</surname><given-names>MA</given-names></name><name><surname>Fini</surname><given-names>MA</given-names></name><name><surname>Graham</surname><given-names>BB</given-names></name><name><surname>Tuder</surname><given-names>RM</given-names></name><name><surname>Friedman</surname><given-names>JE</given-names></name><name><surname>Eltzschig</surname><given-names>HK</given-names></name><name><surname>Sokol</surname><given-names>RJ</given-names></name><name><surname>Stenmark</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension</article-title><source>Journal of Immunology</source><volume>193</volume><fpage>597</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1303048</pub-id><pub-id pub-id-type="pmid">24928992</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frid</surname><given-names>MG</given-names></name><name><surname>McKeon</surname><given-names>BA</given-names></name><name><surname>Thurman</surname><given-names>JM</given-names></name><name><surname>Maron</surname><given-names>BA</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Sullivan</surname><given-names>T</given-names></name><name><surname>Laskowsky</surname><given-names>J</given-names></name><name><surname>Fini</surname><given-names>MA</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Tuder</surname><given-names>RM</given-names></name><name><surname>Gandjeva</surname><given-names>A</given-names></name><name><surname>Wilkins</surname><given-names>MR</given-names></name><name><surname>Rhodes</surname><given-names>CJ</given-names></name><name><surname>Ghataorhe</surname><given-names>P</given-names></name><name><surname>Leopold</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>RS</given-names></name><name><surname>Holers</surname><given-names>VM</given-names></name><name><surname>Stenmark</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immunoglobulin-driven complement activation regulates proinflammatory remodeling in pulmonary hypertension</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>201</volume><fpage>224</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1164/rccm.201903-0591OC</pub-id><pub-id pub-id-type="pmid">31545648</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Guignabert</surname><given-names>C</given-names></name><name><surname>Bonnet</surname><given-names>S</given-names></name><name><surname>Dorfmüller</surname><given-names>P</given-names></name><name><surname>Klinger</surname><given-names>JR</given-names></name><name><surname>Nicolls</surname><given-names>MR</given-names></name><name><surname>Olschewski</surname><given-names>AJ</given-names></name><name><surname>Pullamsetti</surname><given-names>SS</given-names></name><name><surname>Schermuly</surname><given-names>RT</given-names></name><name><surname>Stenmark</surname><given-names>KR</given-names></name><name><surname>Rabinovitch</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives</article-title><source>The European Respiratory Journal</source><volume>53</volume><elocation-id>1801887</elocation-id><pub-id pub-id-type="doi">10.1183/13993003.01887-2018</pub-id><pub-id pub-id-type="pmid">30545970</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Yang</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Schermuly</surname><given-names>RT</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>JM</given-names></name><name><surname>Noh</surname><given-names>TW</given-names></name><name><surname>Lee</surname><given-names>SP</given-names></name><name><surname>Bae</surname><given-names>SS</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Ju</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>JB</given-names></name><name><surname>Kim</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title><italic>Sox17</italic> deficiency promotes pulmonary arterial hypertension via HGF/c-Met signaling</article-title><source>Circulation Research</source><volume>131</volume><fpage>792</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.320845</pub-id><pub-id pub-id-type="pmid">36205124</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>HL</given-names></name><name><surname>Bao</surname><given-names>JH</given-names></name><name><surname>Tang</surname><given-names>JJ</given-names></name><name><surname>Xu</surname><given-names>DY</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Arterial remodeling: the role of mitochondrial metabolism in vascular smooth muscle cells</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>324</volume><fpage>C183</fpage><lpage>C192</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00074.2022</pub-id><pub-id pub-id-type="pmid">36468843</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stacher</surname><given-names>E</given-names></name><name><surname>Graham</surname><given-names>BB</given-names></name><name><surname>Hunt</surname><given-names>JM</given-names></name><name><surname>Gandjeva</surname><given-names>A</given-names></name><name><surname>Groshong</surname><given-names>SD</given-names></name><name><surname>McLaughlin</surname><given-names>VV</given-names></name><name><surname>Jessup</surname><given-names>M</given-names></name><name><surname>Grizzle</surname><given-names>WE</given-names></name><name><surname>Aldred</surname><given-names>MA</given-names></name><name><surname>Cool</surname><given-names>CD</given-names></name><name><surname>Tuder</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Modern age pathology of pulmonary arterial hypertension</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>186</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1164/rccm.201201-0164OC</pub-id><pub-id pub-id-type="pmid">22679007</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenmark</surname><given-names>KR</given-names></name><name><surname>Frid</surname><given-names>MG</given-names></name><name><surname>Graham</surname><given-names>BB</given-names></name><name><surname>Tuder</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension</article-title><source>Cardiovascular Research</source><volume>114</volume><fpage>551</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvy004</pub-id><pub-id pub-id-type="pmid">29385432</pub-id></element-citation></ref></ref-list></back></article>